triazolopyrimidine GCN2 kinase inhibitors (Merck KGaA)

N/A

Report date: 2025/03/20 09:42:31
NME

Base Information

Drug Nametriazolopyrimidine GCN2 kinase inhibitors (Merck KGaA)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic translation initiation factor 2-alpha kinase 4 inhibitors
TargetsEukaryotic translation initiation factor 2-alpha kinase 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck KGaA, Darmstadt, Germany
China Registration ClassN/A

Develop Information

Active CompaniesMerck KGaA, Darmstadt, Germany
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A